Leonhardt Ventures & BioLeonhardt Technology Showcase During ACC Chicago April 2nd, 2016 – New Larger Venue Notice
Los Angeles, CA, Salt Lake City, UT, Chicago, IL – March 31st, 2016 – Leonhardt Ventures and BioLeonhardt to Present Technology Showcase in Chicago, IL just outside of American College Cardiology (ACC) Annual Meeting – co-sponsored by HealthiosXchange – Saturday, April, 2nd, 2016 12 noon to 1:30pm @
Conference Chicago at University Center
525 S State St, Chicago, IL 60605
Just over 2 miles from convention center where ACC Annual Mtg is being held at and a short 5 minute walk from the original 37 Van Buren Genosi Apartel location. Please email email@example.com to RSVP
First combination implantable stem cell/growth factor pump + bioelectric regeneration stimulator for regenerating hearts will be presented – www.bioleonhardt.com + www.myostimpacers.com ; BioLeonhardt related Scientific Supporting Articles – http://www.bioleonhardt.com/supporting-articles/
Leonhardt Ventures Cal-X Stars Accelerator is led by a 37 person Scientific Advisory Board – http://calxstars.com/scientific-advisory-board/ and 73 person Business Advisory Board – http://calxstars.com/team-cal-x/
Innovations to be showcased include:
BioLeonhardt – http://www.bioleonhardt.com ; – first implantable, programmable, re-fillable stem cell pump in combination with bioelectric regeneration stimulation for treating advanced heart failure. Featuring combined utilization of MicroRNAs, time release SDF-1, various growth factors, nutrient hydrogel, cardiac matrix, follistatin, tropinelastin, HGH, HGF, IGF-1, Pyruvate, APO E, Erthropoiten, cardiac stem cells, iPS cells and muscle progenitor stem cells all with programmed repeat deliveries. Bioelectric stimulator causes release of SDF-1, VEGF, follistatin, tropinelastin, HGF from tissues and controls differentiation. Currently in translational study in 55 pigs transitioning to 20 patient pilot trial in Europe.
MyoStim Pacers – http:/www.myostimpacers.com – world’s first heart failure pacemaker designed to recruit reparative stem cells to damaged and weakened heart tissue.
MyoStim Peripheral – electrical stimulation device for treating critical limb ischemia and diabetic foot ulcers, pain relief – http://www.myostimpacers.com/microcurrent-stimulators.php – the Axion device is U.S. FDA 510K market cleared for microcurrent treatments – FDA 510(k) K911814. Data on 47 clinical patients treated with the Wetling (Leonhardt Ventures collaborator) CE Mark approved wireless microcurrent system for treating diabetic foot ulcers in Germany, Switzerland and Denmark will also be presented and well as an introduction to cominbation microcurrent and stem cell + growth factor micro pump healing bandages.
Note – BioLeonhardt and MyoStim are in the process of merging into one entity BioLeonhardt MyoStim.
Cardiobridge – http://www.cardiobridge.com – Highest flow rate 10FR circulatory support catheter pump in clinical testing for acute decompensating heart failure and high-risk PCI. Data on about 30 clinical patients will be presented with exceptional notable improvement in renal function.
Bioheart, Inc.* – http://www.bioheartinc.com – Phase III leader in applying adult muscle stem cells to treat advanced heart failure. Only cell type known to grow new contractile muscle in the depths of scar tissue. *Leonhardt Ventures founded Bioheart, Inc. in 1999 but now is only a minority position shareholder. Bioheart MyoCell in Phase II/III clinical trials beat placebo injections by 95.7 meters in exercise capacity improvement. 84% of Bioheart MyoCell treated patients have improved in at least compared to only 16% of placebo or control patients in clinical studies since 2001.
BioPace – world’s first biological pacemaker made entirely of living cells – https://leonhardtventures.com/biopace.php
CoroStim – world’s first vibrational energy emitting pacemaker that prevents plaque formation and blood clots in high risk coronary arteries, heart chambers, heart valves and devices such as LVADs.
CerebraCell – microcurrent based non-invasive or minimally invasive energy system for brain regeneration. Also non-invasive cerebral aneurysm repair – https://leonhardtventures.com/test.php
AortaCell – https://leonhardtventures.com/aortacell.php ;- Method and device to treat aortic aneurysms non-invasively and minimally invasively with devices that deliver focal wireless electrical energy to weakened aortic wall tissue that causes reparative autologous stem cells to home to that chosen treatment location which are then differentiated into smooth muscle thus reinforcing vessel wall strength. Also a new product developed of 2nd beating heart in aorta.
EndoCell – Method and device for growing new endothelium lining of a damaged artery with a percutaneous needle catheter, endothelial progenitor cells, laser light and biolelectric regeneration energy.
Valvublator – Percutaneous catheter device for de-calcifying, cell sodding and regenerating heart valve leaflets so a patient may keep their own valve instead of getting an artificial implant – www.valvublator.com + https://leonhardtventures.com/valbulator.php Also tissue engineered heart valves.
HeartScore + NI Medical – Total Heart Failure Management System, heart failure and cardiovascular genomics, lung water necklace, @ home monitoring, smart phone app and high fidelity noise free ECG analysis – www.heartscore.co + http://heartscore.co/heart-failure-management/ + www.heartgenomics.com + www.vivaquant.com HeartScore is also getting ready to publish the Top 100 Cardiovascular Innovations of 2015/16 eMagazine as well.
BioLeonhardt Whole Body – Developing whole body regeneration chamber designed to take 30 years off age and add 30 years extension to life (early stage development).
In addition to the above cardiovascular focused startups Leonhardt Ventures and Cal-X Stars Business Accelerator, Inc. is incubating EyeCell (eye) -https://leonhardtventures.com/eyecell.php, PancreaCell, RegenaLung, MyoStim Skin, MyoStim ED – erectile dysfunction recovery, Stem Cell Bra (breast www.stemcellbra.com), OrothodontiCell (accelerating teeth movement), DentaCell (dental gums healing) – https://leonhardtventures.com/denta-call.php, all utilizing microcurrent energy technology to direct stem cell and growth factor expression based healing. CancerCell another new spin out just filed a patent pending for bioelectric signaling that causes cell division to stop and halts blood flow to cancer tumors followed by a regeneration program.
About Leonhardt Ventures: Since 1982 Leonhardt Ventures www.lventuresnestg.wpenginepowered.com has a strong history of inventing, developing, backing and bringing to market leadership products for treating heart and cardiovascular disease. Over 250,000 patients have been treated to date with Leonhardt inventions. In the 1980’s the group developed market leadership in patented cardiovascular polyurethane balloon catheters including drug, stem cell and radiation delivery systems, electrical stimulation devices for improving blood flow and also turn-key cath labs. In the 1990s they developed over 20 additional devices including the first commercially successful stent graft for aortic aneurysm repair (TALENT – Taheri-Leonhardt Stent Graft) – SEE VIDEO https://vimeo.com/85232193, the first percutaneous heart valve, intravascular lung catheter, the Pro-Cell intracavity stem cell delivery system and the MyoCath line of stem cell delivery catheters. Leonhardt patented inventions – http://patents.justia.com/inventor/howard-j-leonhardt ;- include the first heart failure pacemaker able to recruit reparative stem cells to damaged heart tissue (MyoStim Pacers – www.myostimpacers.com). In 2001 the team led the first in the world non-surgical case of stem cell repair of damaged heart muscle in a human patient with Bioheart MyoCell . That led to the first Phase II/III double blinded, randomized, placebo controlled trial for muscle stem cells growing new contractile muscle in post heart attack tissue in advanced heart failure patients – results published in the American Heart Journal Bioheart MyoCell patients 95.7 meters improvement in exercise capacity over placebo (minus 4 meters decline). The Leonhardt led team at BioPace is preparing to complete the first ever biological pacemaker implantation made entirely of living cells in a human patient within the next 12-18 months. For more Leonhardt Ventures information – https://leonhardtventures.com/about-us.php 1Q 2015 Newsletter and 2014 Annual Report – http://us5.campaign-archive2.com/?u=3a3ec29e83782844c8ac560f9&id=158fdee643
About Cal-X Stars Business Accelerator, Inc www.calxstars.com: Leonhardt Ventures’ organized the Cal-X Stars Business Accelerator, Inc. www.calxstars.com in 2013 to serve as a 5 year business accelerator for cardiovascular life science and social good impact innovations and startups. The Cal-X Stars 2015 class portfolio includes 20 regenerative medtech and 15 regenerative economy startups.
About Healthiosxchange: The HealthiosXchange www.healthioxschange.com is the premiere investment marketplace dedicated exclusively to the global healthcare industry. Employing crowd funding as the cornerstone of a new paradigm in healthcare investing, the HealthiosXchange offers direct access to the broadest investment opportunities on a “Fee Free, Carry Free” basis in the most trusted online environment. The HealthiosXchange is an affiliate of Healthios Capital Markets, LLC., a FINRA-regulated broker dealer based in Chicago, with offices in Boston, London, Geneva, and Bangkok. Healthioxchange is a leader in self directed IRA financings with accredited investors into syndicates led by proven track record industry leaders.
Healthiosxchange is the official listing board for the the Cal-X Stars Business Accelerator, Inc. $15 million offering via 506D part C. This exemption allows general solicitation and up to 2000 accredited investors. Any potential investor’s accredited status must be verified by a broker, lawyer, accountant or other verifiable means. Cal-X Stars Business Accelerator is incubating/accelerating by charter 15 cardiovascular and 15 social good impact startup innovations with intention to start auctioning them off to the highest bidders starting May 11th, 2018. By charter Cal-X Stars Business Accelerator, Inc will not accept any self directed IRA investments that exceed 10% of a person’s IRA total portfolio and we recommend 5% due to the very high risk nature of investing in early stage cardiovascular and social good impact startups such as those incubating within the Cal-X Stars accelerator. Any potential investor should read all risk factors published in our private placement memorandum.
SOURCE Leonhardt Ventures and BioLeonhardt, 1531 6th Street, Unit 401, Santa Monica, CA + Leonhardt’s Launchpads Utah, 489E 400 South, Salt Lake City, Utah 84111 email: firstname.lastname@example.org